Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles Sells 12,691 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) CEO Patrick Miles sold 12,691 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the sale, the chief executive officer now owns 5,857,603 shares in the company, valued at $62,324,895.92. The trade was a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Patrick Miles also recently made the following trade(s):

• On Wednesday, February 26th, Patrick Miles sold 32,393 shares of Alphatec stock. The shares were sold at an average price of $10.89, for a total transaction of $352,759.77.
• On Wednesday, February 5th, Patrick Miles sold 43,459 shares of Alphatec stock. The shares were sold at an average price of $11.95, for a total transaction of $519,335.05.
• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The shares were sold at an average price of $12.03, for a total transaction of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total value of $80,244.00.

Alphatec Stock Up 2.9 %

Alphatec stock traded up $0.28 during midday trading on Tuesday, hitting $9.95. 1,865,519 shares of the company were exchanged, compared to its average volume of 1,980,446. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $14.88. The company's fifty day moving average price is $10.92 and its 200-day moving average price is $8.66. The company has a market cap of $1.43 billion, a PE ratio of -7.77 and a beta of 1.39.

Remove Ads

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). The company had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ATEC. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Alphatec by 11.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock worth $16,280,000 after acquiring an additional 297,850 shares during the last quarter. Barclays PLC lifted its stake in Alphatec by 362.3% in the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock valued at $948,000 after buying an additional 133,653 shares during the period. Franklin Resources Inc. grew its holdings in Alphatec by 299.3% during the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock valued at $343,000 after purchasing an additional 48,308 shares during the period. Royce & Associates LP grew its holdings in shares of Alphatec by 15.9% in the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company's stock valued at $6,740,000 after buying an additional 165,954 shares during the period. Finally, State Street Corp raised its position in shares of Alphatec by 10.1% during the third quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock worth $17,453,000 after purchasing an additional 287,350 shares during the period. Institutional investors and hedge funds own 66.35% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. Barclays raised their target price on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. Piper Sandler lifted their price objective on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Thursday, February 27th. Finally, StockNews.com raised shares of Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Alphatec has a consensus rating of "Moderate Buy" and a consensus target price of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.